
Jose Luis Perez-Gracia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9546999/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. Cancer Letters, 2022, 529, 70-84.	7.2	51
2	A phase lb, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2022, 40, 95-95.	1.6	4
3	Molecular biomarkers of prognosis in advanced renal cell carcinoma patients treated with Pazopanib plus interferon alpha (INF-2A) in a phase I/IIstudy by the Spanish Oncology Genitourinary Group. Clinical Genitourinary Cancer, 2022, , .	1.9	0
4	Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. European Urology Focus, 2021, 7, 1084-1091.	3.1	4
5	Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies. Clinical and Translational Oncology, 2021, 23, 882-891.	2.4	5
6	Paradigms on Immunotherapy Combinations with Chemotherapy. Cancer Discovery, 2021, 11, 1353-1367.	9.4	197
7	Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 1327-1337.	2.8	3
8	Retrospective study for the characterization of COVID-19 in renal cancer (COVID-REN) patients treated with antiangiogenics or immunotherapy and outcome comparison with non-infected cases Journal of Clinical Oncology, 2021, 39, 4577-4577.	1.6	0
9	Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762) Journal of Clinical Oncology, 2021, 39, 4556-4556.	1.6	5
10	Characterization of the perioperative changes of exosomal immune-related cytokines induced by prostatectomy in early-stage prostate cancer patients. Cytokine, 2021, 141, 155471.	3.2	6
11	A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer. Translational Research, 2021, 233, 77-91.	5.0	15
12	Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on <scp>IL</scp> â€8. Journal of Pathology, 2021, 255, 190-201.	4.5	49
13	579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naìve metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology, 2021, 32, S629-S630.	1.2	13
14	Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 1718-1732.	1.1	141
15	Designing clinical studies for biomarker discovery: The Design criteria. , 2020, , 441-466.		0
16	Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. Nature Cancer, 2020, 1, 75-85.	13.2	68
17	Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors. Science Translational Medicine, 2020, 12, .	12.4	51
18	Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 452-460.	1.9	11

#	Article	IF	CITATIONS
19	Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nature Medicine, 2020, 26, 688-692.	30.7	296
20	ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy. ESMO Open, 2020, 5, e000662.	4.5	15
21	Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. Journal of Clinical Oncology, 2020, 38, 1580-1590.	1.6	189
22	CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity. Immunity, 2020, 52, 856-871.e8.	14.3	387
23	Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors. Oncolmmunology, 2020, 9, 1760676.	4.6	4
24	Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1341-1348.	2.3	7
25	Unnecessary test ordering in clinical trials: human chorionic gonadotropin as an example. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.2	0
26	TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies. Molecular Cancer Therapeutics, 2019, 18, 621-631.	4.1	68
27	Comparison of six commercial serum exosome isolation methods suitable for clinical laboratories. Effect in cytokine analysis. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1539-1545.	2.3	74
28	Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. Clinical Cancer Research, 2019, 25, 4663-4673.	7.0	210
29	Immunotherapeutic effects of intratumoral nanoplexed poly I:C. , 2019, 7, 116.		91
30	Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature, 2019, 569, 428-432.	27.8	313
31	Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer. International Journal of Cancer, 2019, 145, 1991-2001.	5.1	32
32	Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nature Medicine, 2019, 25, 470-476.	30.7	459
33	The Dynamic Use of <i>EGFR</i> Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients. Disease Markers, 2019, 2019, 1-7.	1.3	13
34	Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study. Medical Oncology, 2019, 36, 29.	2.5	0
35	Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. European Journal of Cancer, 2019, 107, 186-195.	2.8	11
36	Cytokines in clinical cancer immunotherapy. British Journal of Cancer, 2019, 120, 6-15.	6.4	720

#	Article	IF	CITATIONS
37	Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Annals of Oncology, 2019, 30, 281-289.	1.2	88
38	Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study Journal of Clinical Oncology, 2019, 37, 264-264.	1.6	4
39	Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC) Journal of Clinical Oncology, 2019, 37, 394-394.	1.6	6
40	Durability of complete response (CR) with atezolizumab (atezo) in locally advanced/metastatic urothelial carcinoma (mUC) Journal of Clinical Oncology, 2019, 37, 4527-4527.	1.6	0
41	Whole exome sequencing of germline DNA of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung adenocarcinoma (LUAD) according to KRAS status Journal of Clinical Oncology, 2019, 37, 1540-1540.	1.6	1
42	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. European Urology, 2018, 73, 462-468.	1.9	36
43	Radium-223 international early access program: results from the Spanish subset. Future Oncology, 2018, 14, 41-50.	2.4	3
44	Reply to Francesco Massari and Vincenzo Di Nunno's Letter to the Editor re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462–8. European Urology, 2018, 74, e14.	1.9	0
45	Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. Annals of Oncology, 2018, 29, 1312-1319.	1.2	106
46	Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4–1BB). Oncolmmunology, 2018, 7, e1368605.	4.6	7
47	SEOM clinical guideline for treatment of kidney cancer (2017). Clinical and Translational Oncology, 2018, 20, 47-56.	2.4	15
48	Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better?. Translational Lung Cancer Research, 2018, 7, S356-S357.	2.8	8
49	Phase II study of paclitaxel and TAK-228 in metastatic urothelial carcinoma and the impact of PI3K-mTOR pathway genomic alterations. Annals of Oncology, 2018, 29, viii326.	1.2	Ο
50	Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors. Annals of Oncology, 2018, 29, viii732.	1.2	8
51	A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis. , 2018, 6, 96.		40
52	International Symposium: Trailblazing in Cancer Immunotherapy, October 29–31, 2017, Pamplona, Spain. Cancer Immunology, Immunotherapy, 2018, 67, 1809-1813.	4.2	0
53	Liquid Biopsy: From Basic Research to Clinical Practice. Advances in Clinical Chemistry, 2018, 83, 73-119.	3.7	49
54	Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer. Cancer Medicine, 2018, 7, 3474-3483.	2.8	11

#	Article	IF	CITATIONS
55	Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes. Clinical Cancer Research, 2018, 24, 6115-6124.	7.0	14
56	A novel proteinâ€based prognostic signature improves risk stratification to guide clinical management in earlyâ€stage lung adenocarcinoma patients. Journal of Pathology, 2018, 245, 421-432.	4.5	29
57	Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e1133-e1139.	1.9	18
58	Abstract CT017: Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. , 2018, , .		1
59	Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210 Journal of Clinical Oncology, 2018, 36, 4523-4523.	1.6	29
60	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	7.7	80
61	Pazopanib-induced asymptomatic radiological acute pancreatitis: A case report. Molecular and Clinical Oncology, 2017, 6, 651-654.	1.0	3
62	A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). Annals of Oncology, 2017, 28, 1517-1522.	1.2	16
63	Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Annals of Oncology, 2017, 28, 1988-1995.	1.2	326
64	Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA;) Tj ETQq0 0 0 1 2017, 18, 672-681a.	rgBT /Ovei 10.7	lock 10 Tf 50
65	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet, The, 2017, 389, 67-76.	13.7	1,728
66	Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Annals of Oncology, 2017, 28, xii44-xii55.	1.2	170
67	Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Annals of Oncology, 2017, 28, 3044-3050.	1.2	198
68	Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies. Brachytherapy, 2017, 16, 1246-1251.	0.5	32
69	Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treatment Reviews, 2017, 60, 24-31.	7.7	262
70	HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma. OncoTargets and Therapy, 2017, Volume 10, 4635-4643.	2.0	10
71	First-in-human clinical trial with intratumoral BO-112 in solid malignancies: A novel immunotherapy based in double-stranded RNA (dsRNA) Journal of Clinical Oncology, 2017, 35, 3082-3082.	1.6	3
72	Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010 Journal of Clinical Oncology, 2017, 35, 9090-9090.	1.6	14

#	Article	IF	CITATIONS
73	Lymphocytes and neutrophils count after two cycles and TTF1 expression as early outcome predictors during immunotherapy (IT) in stage IV non-small cell lung cancer (NSCLC) patients Journal of Clinical Oncology, 2017, 35, e20553-e20553.	1.6	3
74	Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Outcomes by prior therapy Journal of Clinical Oncology, 2017, 35, 323-323.	1.6	4
75	A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma Journal of Clinical Oncology, 2017, 35, 349-349.	1.6	19
76	ld1 and ld3 genes confer poor prognosis in KRAS-mutant (KM) lung adenocarcinoma (LA) patients. Gene silencing reduces metastatic rate to the liver and increases survival. Annals of Oncology, 2016, 27, vi440.	1.2	0
77	Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy. Cancer Discovery, 2016, 6, 1312-1314.	9.4	41
78	PD27-12 PRIMARY ANALYSIS OF IMVIGOR 210: ATEZOLIZUMAB IN PLATINUM-TREATED ADVANCED UROTHELIAL CARCINOMA. Journal of Urology, 2016, 195, .	0.4	0
79	Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2016, 22, 5461-5471.	7.0	234
80	PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New TumorÂSamples for PD-L1 Assessment. Journal of Thoracic Oncology, 2016, 11, S174-S175.	1.1	6
81	Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value. Tumor Biology, 2016, 37, 13687-13694.	1.8	37
82	Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. Cancer Research, 2016, 76, 5994-6005.	0.9	191
83	Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study. Annals of Oncology, 2016, 27, vi270.	1.2	8
84	Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010. Annals of Oncology, 2016, 27, vi583.	1.2	6
85	Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism. Oncolmmunology, 2016, 5, e1062967.	4.6	52
86	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, The, 2016, 387, 1540-1550.	13.7	5,456
87	Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes. Brachytherapy, 2016, 15, 127-135.	0.5	13
88	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti–PD-1 and Anti-CD137 Monoclonal Antibodies. Journal of Thoracic Oncology, 2016, 11, 524-536.	1.1	48
89	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, The, 2016, 387, 1909-1920.	13.7	3,077
90	Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs). Clinical Cancer Research, 2016, 22, 3924-3936.	7.0	306

#	Article	IF	CITATIONS
91	Circulating melanoma exosomes as diagnostic and prognosis biomarkers. Clinica Chimica Acta, 2016, 454, 28-32.	1.1	134
92	Stereotactic body radiation therapy (SBRT) delays the emergence of castration resistance in patients with oligometastatic prostate cancer. Clinical and Translational Oncology, 2016, 18, 743-747.	2.4	8
93	Dual modulation of MCL-1 and mTOR determines the response to sunitinib. Journal of Clinical Investigation, 2016, 127, 153-168.	8.2	49
94	PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210) Journal of Clinical Oncology, 2016, 34, 104-104.	1.6	32
95	Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC Journal of Clinical Oncology, 2016, 34, 3030-3030.	1.6	4
96	A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results Journal of Clinical Oncology, 2016, 34, 3056-3056.	1.6	18
97	Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC Journal of Clinical Oncology, 2016, 34, 9015-9015.	1.6	10
98	Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010 Journal of Clinical Oncology, 2016, 34, 9024-9024.	1.6	7
99	IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC) Journal of Clinical Oncology, 2016, 34, 355-355.	1.6	45
100	Phase II study of pazopanib plus interferon alfa as first-line therapy of advanced renal cell carcinoma: A Spanish Oncology Genitourinary Group (SOGUG) study Journal of Clinical Oncology, 2016, 34, 4571-4571.	1.6	0
101	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2â^'/â^'IL2Rγnull Immunodeficient Mice. Cancer Research, 2015, 75, 3466-3478.	0.9	137
102	Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nature Reviews Cancer, 2015, 15, 457-472.	28.4	576
103	Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. Seminars in Oncology, 2015, 42, 640-655.	2.2	179
104	Functional expression of CD137 (4-1BB) on T helper follicular cells. Oncolmmunology, 2015, 4, e1054597.	4.6	15
105	Variations in Molecular Profile in NSCLC Can Be Analyzed Using Cytological Samples. International Journal of Surgical Pathology, 2015, 23, 111-115.	0.8	10
106	Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors. Clinical Chemistry, 2015, 61, 297-304.	3.2	221
107	Abstract 261: Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2RÎ ³ null immunodeficient mice. , 2015, , .		3
108	Determining viability of circulating tumor cells (CTCs) as a predictive biomarker for response in patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with Radium 223 (Ra) Journal of Clinical Oncology, 2015, 33, e16051-e16051.	1.6	0

#	Article	IF	CITATIONS
109	Familial clustering of lung cancer (LC) cases in a south European population (sEp) Journal of Clinical Oncology, 2015, 33, e12621-e12621.	1.6	0
110	Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma. PLoS ONE, 2014, 9, e86263.	2.5	76
111	Phase li Study with Immunotherapy with Dendritic Cells (Dc) Combined with Intratumoral Hiltonol in Patients with Advanced Cancer. Annals of Oncology, 2014, 25, iv371.	1.2	0
112	Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins. Clinical Cancer Research, 2014, 20, 5697-5707.	7.0	200
113	Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours. Clinical and Translational Oncology, 2014, 16, 322-329.	2.4	18
114	Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Current Opinion in Immunology, 2014, 27, 89-97.	5.5	111
115	Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. Clinica Chimica Acta, 2014, 429, 168-174.	1.1	20
116	Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2058-2065.	6.4	75
117	Genome Wide Association Study (Gwas) for Identification of Single Nucleotide Polymorphisms (Snps) Associated with Individuals Presenting Extreme Phenotypes of Tobacco Induced Non-Small Cell Lung Cancer (Nsclc) Risk. Annals of Oncology, 2014, 25, iv548.	1.2	0
118	Identification through genome-wide association study (GWAS) of single nucleotide polymorphisms (SNPs) associated with extreme phenotypes of tobacco-induced non-small cell lung cancer (NSCLC) risk Journal of Clinical Oncology, 2014, 32, 11046-11046.	1.6	1
119	Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial Journal of Clinical Oncology, 2014, 32, 5012-5012.	1.6	30
120	Randomized Pharmacokinetic Study Comparing Subcutaneous and Intravenous Palonosetron in Cancer Patients Treated with Platinum Based Chemotherapy. PLoS ONE, 2014, 9, e89747.	2.5	8
121	Randomized phase II study with dendritic cell (DC) immunotherapy in patients with resected hepatic metastasis of colorectal carcinoma Journal of Clinical Oncology, 2014, 32, TPS3129-TPS3129.	1.6	0
122	Phase II study with immunotherapy with dendritic cells (DC) and intratumoral hiltonol in patients with advanced solid tumors Journal of Clinical Oncology, 2014, 32, TPS3113-TPS3113.	1.6	0
123	Serum interleukin-8 and its relationship to tumor burden and treatment response across malignancies of multiple tissue origins Journal of Clinical Oncology, 2014, 32, e22135-e22135.	1.6	0
124	Integrated genomic analysis for revealing broad remodeling of EGFR-targeted therapy resistant lung cancers Journal of Clinical Oncology, 2014, 32, 8083-8083.	1.6	0
125	Abstract 954: Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer patients with acquired resistance to erlotinib. , 2014, , .		0
126	Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC). Clinical and Translational Oncology, 2013, 15, 698-704.	2.4	13

Jose Luis Perez-Gracia

#	Article	IF	CITATIONS
127	A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. Journal of Hepatology, 2013, 59, 81-88.	3.7	816
128	Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination. Clinical Cancer Research, 2013, 19, 997-1008.	7.0	161
129	Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer. Journal of the National Cancer Institute, 2013, 105, 1385-1393.	6.3	127
130	Phase I/II study of biweekly pemetrexed plus cisplatin in patients with locally advanced, nonresectable or metastatic urothelial cancer: Safety and efficacy results from phase II Journal of Clinical Oncology, 2013, 31, 4550-4550.	1.6	60
131	A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL) Journal of Clinical Oncology, 2013, 31, TPS3107-TPS3107.	1.6	7
132	EGFR-activating mutations and treatment with tyrosine-kinase inhibitors (TKI) to revert poor-prognosis (PP) associated with liver metastases (LM) in stage IV non-small cell lung cancer (NSCLC) patients (pts) Journal of Clinical Oncology, 2013, 31, e19106-e19106.	1.6	0
133	Clinical validation of mutational analysis of EGFR and KRAS in fine needle aspiration and small core needle biopsies using a real-time PCR method Journal of Clinical Oncology, 2013, 31, e19027-e19027.	1.6	0
134	Adrenalectomy for low-tumor-burden metastatic lung cancer: Results of a single institution experience Journal of Clinical Oncology, 2013, 31, e19114-e19114.	1.6	0
135	Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with acquired resistance to erlotinib Journal of Clinical Oncology, 2013, 31, 11010-11010.	1.6	1
136	Cardiotrophin-1 determines liver engraftment of syngenic colon carcinoma cells through an immune system-mediated mechanism. Oncolmmunology, 2012, 1, 1527-1536.	4.6	8
137	The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy. Cancer Discovery, 2012, 2, 608-623.	9.4	156
138	External-Beam Radiation Therapy and High–Dose Rate Brachytherapy Combined With Long-Term Androgen Deprivation Therapy in High and Very High Prostate Cancer: Preliminary Data on Clinical Outcome. International Journal of Radiation Oncology Biology Physics, 2012, 82, e469-e476.	0.8	39
139	Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). Clinical and Translational Oncology, 2012, 14, 564-574.	2.4	12
140	The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience. Clinical and Translational Oncology, 2012, 14, 835-841.	2.4	6
141	Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review Radiation Oncology, 2012, 7, 50.	2.7	21
142	Safety and efficacy of maintenance therapy (MT) with a nonspecific cytochrome-P 17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castratation-resistant prostate cancer (mCRPC) patients Journal of Clinical Oncology, 2012, 30, 145-145.	1.6	0
143	Vinflunine maintenance therapy versus best supportive care (BSC) after platinum combination in advanced bladder cancer: A phase II, randomized, open-label study (MAJA study)—SOGUG 2011-02 Journal of Clinical Oncology, 2012, 30, TPS4674-TPS4674.	1.6	0
144	Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes. Cancer Research, 2011, 71, 801-811.	0.9	137

JOSE LUIS PEREZ-GRACIA

#	Article	IF	CITATIONS
145	Carcinoma-Derived Interleukin-8 Disorients Dendritic Cell Migration Without Impairing T-Cell Stimulation. PLoS ONE, 2011, 6, e17922.	2.5	36
146	Dendritic Cells Take up and Present Antigens from Viable and Apoptotic Polymorphonuclear Leukocytes. PLoS ONE, 2011, 6, e29300.	2.5	27
147	SEOM clinical guidelines for using molecular markers in clinical practice. Clinical and Translational Oncology, 2011, 13, 587-591.	2.4	0
148	Synergistic effects of CTLAâ€4 blockade with tremelimumab and elimination of regulatory T lymphocytes <i>in vitro</i> and <i>in vivo</i> . International Journal of Cancer, 2011, 129, 374-386.	5.1	16
149	Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Annals of Oncology, 2011, 22, 2646-2653.	1.2	109
150	Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients. Journal of Immunology, 2011, 187, 6130-6142.	0.8	59
151	Assessment of Epidermal Growth Factor Receptor and K-Ras Mutation Status in Cytological Stained Smears of Non-Small Cell Lung Cancer Patients: Correlation with Clinical Outcomes. Oncologist, 2011, 16, 877-885.	3.7	75
152	Direct Effects of Type I Interferons on Cells of the Immune System. Clinical Cancer Research, 2011, 17, 2619-2627.	7.0	390
153	Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunology, Immunotherapy, 2010, 59, 1223-1233.	4.2	107
154	Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells. Cancer Immunology, Immunotherapy, 2010, 59, 1621-1631.	4.2	38
155	Selection of extreme phenotypes: the role of clinical observation in translational research. Clinical and Translational Oncology, 2010, 12, 174-180.	2.4	34
156	Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic) Tj ETQq0 0 0 rgBT /	Overlock 1 10.7	.0 Tf 50 307 64
157	Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. Annals of Oncology, 2009, 20, 1803-1812.	1.2	23
158	Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?. Immunotherapy, 2009, 1, 845-853.	2.0	17
159	<i>In vivo</i> depletion of DC impairs the antiâ€tumor effect of agonistic antiâ€CD137 mAb. European Journal of Immunology, 2009, 39, 2424-2436.	2.9	47
160	Non-O1 Vibrio cholerae inguinal skin and soft tissue infection with bullous skin lesions in a patient with a penis squamous cell carcinoma. Annals of Clinical Microbiology and Antimicrobials, 2009, 8, 17.	3.8	12
161	Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. British Journal of Cancer, 2009, 100, 1111-1119.	6.4	183
162	Toxic Epidermal Necrolysis Related to Pemetrexed and Carboplatin with Vitamin B12 and Folic Acid Supplementation for Advanced Non-Small Cell Lung Cancer. Onkologie, 2009, 32, 580-584.	0.8	24

JOSE LUIS PEREZ-GRACIA

#	Article	IF	CITATIONS
163	Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. British Journal of Cancer, 2009, 101, 1876-1883.	6.4	79
164	Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer. World Journal of Gastroenterology, 2009, 15, 2290.	3.3	14
165	Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma. Clinical and Translational Oncology, 2008, 10, 372-374.	2.4	1
166	Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells. Gene Therapy, 2008, 15, 473-483.	4.5	20
167	Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends in Pharmacological Sciences, 2008, 29, 383-390.	8.7	100
168	Polly Matzinger's "danger model―finds its predicted danger-denoting self moieties. Inmunologia (Barcelona, Spain: 1987), 2008, 27, 205-211.	0.1	2
169	Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma. Clinical Cancer Research, 2008, 14, 6895-6906.	7.0	79
170	Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients Treated with Platinumâ€Based Chemotherapy. Oncologist, 2007, 12, 1151-1155.	3.7	15
171	Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer. Expert Opinion on Biological Therapy, 2007, 7, 599-615.	3.1	22
172	The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFNÎ ³ . International Journal of Cancer, 2007, 121, 1282-1295.	5.1	16
173	Immunotherapy and immunoescape in colorectal cancer. World Journal of Gastroenterology, 2007, 13, 5822.	3.3	36
174	A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer. International Journal of Gynecological Cancer, 2006, 16, 71-76.	2.5	78
175	Immunogenic Cell Death and Cross-Priming Are Reaching the Clinical Immunotherapy Arena: Fig. 1 Clinical Cancer Research, 2006, 12, 2385-2389.	7.0	25
176	Recombinant Adenoviral Vectors Turn on the Type I Interferon System without Inhibition of Transgene Expression and Viral Replication. Molecular Therapy, 2006, 14, 129-138.	8.2	38
177	Activity of Gefitinib in Central Nervous System Metastases in Patients with Non–Small-Cell Lung Cancer: Two Case Reports and a Review of the Literature. Clinical Lung Cancer, 2005, 7, 138-140.	2.6	12
178	Assessment of the value of confirming responses in clinical trials in oncology. European Journal of Cancer, 2005, 41, 1528-1532.	2.8	7
179	Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer. Anti-Cancer Drugs, 2002, 13, 839-845.	1.4	23
180	6 The Role of extreme phenotype selection in cancer research. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2002, , 65-71.	0.0	0

#	Article	IF	CITATIONS
181	The role of extreme phenotype selection studies in the identification of clinically relevant genotypes in cancer research. Cancer, 2002, 95, 1605-1610.	4.1	24
182	Tamoxifen Therapy for Ovarian Cancer in the Adjuvant and Advanced Settings: Systematic Review of the Literature and Implications for Future Research. Gynecologic Oncology, 2002, 84, 201-209.	1.4	89
183	Granulocyte Colony-Stimulating Factor in the Treatment of High-Risk Febrile Neutropenia: a Multicenter Randomized Trial. Journal of the National Cancer Institute, 2001, 93, 31-38.	6.3	152
184	High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial. Bone Marrow Transplantation, 2001, 27, 117-123.	2.4	3